In this study, we hypothesize that CuET, the primary anticancer metabolite derived from DSF, may serve as an immunomodulator within the NKG2D-NKG2DL axis, enhancing the effector functions of NK, NKT, and T cell against CRC. Here, KLRK1 is linked to colorectal carcinoma.